Dorsomorphin (Compound C) (Synonyms: Compound C) |
|
Catalog No.GC17243
|
Dorsomorphin (Compound C) is an agent that used as a cell-permeable AMPK inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 866405-64-3
Sample solution is provided at 25 µL, 10mM.
- J Agr Food Chem (2026).PMID:42385689
- Int J Mol Med 54.3 (2024):1-17.PMID:38963051
- Am J Cancer Res 14.3 (2024):1121.PMID:38590396
- Life Sci 357 (2024):123084.PMID:39374570
- Biochem Bioph Res Co 529.3 (2020):834-838.PMID:32595039
- Toxicol In Vitro 76 (2021):105226.PMID:34293431
- Reproduction (2026):xaag050.PMID:42093080
- Sci Rep-Uk (2026).PMID:42225680
- Reproduction 171.6 (2026):xaag050.PMID:42093080
- Front Biosci-Landmrk: (2026).
- IMMUNOBIOLOGY (2025):152893.PMID:40139125
- J. Biochem. Mol. Toxicol. 39.5 (2025):e70282.PMID:40272051
- J Radiat Res Appl Sc 19.2 (2026):102397.
- Iran J Public Health 54.6 (2025):1263-1271.
- J Inflamm Res (2023):1045-1057.PMID:36936349
- Neuropsych Dis Treat (2023):2657-2671.PMID:38077236
- Int J Mol Sci 24.15 (2023):12329.PMID:37569705
- J Chinese Pharm Sci 35.4 (2026):359.
- Biology: (2026): 1580.
Dorsomorphin (Compound C) is a potent, cell-permeable dual inhibitor of AMPK and BMP pathways (Ki value of 109nM for AMPK).Dorsomorphin competitively binds to the ATP site of AMPK to inhibit AMPK activity and block cellular energy sensing. At the same time, Dorsomorphin inhibits BMP type I receptors ALK2/ALK3/ALK6 to block SMAD1/5/8 phosphorylation. Dorsomorphin can be used in stem cell differentiation, tumor and metabolism research[1-4].
In vitro, Dorsomorphin (5μM) treated Jurkat, U937, Molt4 and other acute lymphoblastic leukemia and acute myeloid leukemia cell lines for 24h. Dorsomorphin inhibited AMPKα autophosphorylation and phosphorylation of downstream AMPK substrates including Beclin 1, Raptor, ULK1, ACC in cells. Dorsomorphin enhanced mitochondrial pathway cell death[5]. Dorsomorphin (5μM) combined with differentiation inducers (3-isobutyl-1-methylxanthine 0.5mM, dexamethasone 0.25μM, insulin 10μg/ml) treated 3T3-L1 preadipocytes for 8 days. Dorsomorphin significantly reduced lipid accumulation in 3T3-L1 preadipocytes[6].
In vivo, Dorsomorphin (10mg/kg; single tail vein injection) combined with recombinant human GPNMB (rGPNMB; single intracerebroventricular injection) was given to CD-1 male mice with subarachnoid hemorrhage (SAH) model at 1h after SAH modeling. Dorsomorphin reduced the p-AMPK/AMPK ratio in mice. Dorsomorphin reversed the downregulation of p-NFκB, IL-1β, IL-6 and TNF-α caused by rGPNMB. Dorsomorphin counteracted the alleviation of brain edema, blood-brain barrier disruption and neurological deficits mediated by rGPNMB[7]. Dorsomorphin (10mg/kg) was intraperitoneally injected into APP/PS1 mice 1h before each aerobic exercise session for 8 weeks. Dorsomorphin eliminated the promotion of p300 nuclear translocation, upregulation of hippocampal H4K5ac and H4K12ac, and enrichment of histone acetylation at GluN1 promoter region induced by aerobic exercise. Dorsomorphin counteracted the improvements in CA1 dendritic spine density, LTP and contextual fear memory enhanced by aerobic exercise[8].
References:
[1] Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108(8):1167-74.
[2] Kim YM, Kim MY, Kim HJ, et al. Compound C independent of AMPK inhibits ICAM-1 and VCAM-1 expression in inflammatory stimulants-activated endothelial cells in vitro and in vivo. Atherosclerosis. 2011 Nov;219(1):57-64.
[3] Saito S, Furuno A, Sakurai J, et al. Compound C prevents the unfolded protein response during glucose deprivation through a mechanism independent of AMPK and BMP signaling. PLoS One. 2012;7(9):e45845.
[4] Guo Y, Zhang Y, Hong K, et al. AMPK inhibition blocks ROS-NFκB signaling and attenuates endotoxemia-induced liver injury. PLoS One. 2014 Jan 24;9(1):e86881.
[5] Jia J, Ji W, Saliba AN, et al. AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death. Cell Death Differ. 2024;31(3):405-416.
[6] Suenaga M, Matsui T, Funaba M. BMP Inhibition with Dorsomorphin Limits Adipogenic Potential of Preadipocytes. J Vet Med Sci. 2010;72(3):373-377.
[7] Li T, Zhang Y, Lu Q, et al. GPNMB Ameliorates Neuroinflammation Via the Modulation of AMPK/NFkB Signaling Pathway After SAH in Mice. J Neuroimmune Pharmacol. 2023;18(6):628-639.
[8] Chai G, Gao T, Bi S, et al. Aerobic exercise facilitates p300 nuclear translocation via ADRB2-AMPKα signaling, leading to enhanced histone acetylation and mitigation of cognitive decline in APP/PS1 mice. Alzheimer's Res Ther. 2026;18:62.
| Cell experiment [1]: | |
|
Cell lines |
Jurkat, Molt4, CEM, REH, Nalm6 (acute lymphoblastic leukemia, ALL), U937, THP.1, ML-1, HL-60, KG1A, MV-4-11, SET2 (acute myeloid leukemia, AML), K562, HEL (blast phase of chronic myeloid leukemia) cell lines |
|
Preparation Method |
Above acute leukemia cell lines were maintained in RPMI 1640 containing 10% heat-inactivated fetal bovine serum (FBS), 100U/mL penicillin G, 100μg/mL streptomycin and 2mM glutamine at densities below 10⁶ cells/mL. Cells were treated with Dorsomorphin for 24h. |
|
Reaction Conditions |
5μM; 24h |
|
Applications |
Dorsomorphin induced cell death. Dorsomorphin suppressed AMPKα autophosphorylation and phosphorylation of downstream AMPK substrates including Beclin 1, Raptor, ULK1 and ACC, promoted dephosphorylation of the proapoptotic protein BAD at Ser75 and Ser99, facilitated BAD translocation to mitochondria to bind BCLXL, and further increased BAK activation, procaspase-9/procaspase-3/PARP1 cleavage, with partial involvement of GSDME-mediated pyroptosis. |
| Animal experiment [2]: | |
|
Animal models |
Male CD-1 (ICR) mice, subarachnoid hemorrhage (SAH) model established by intra-arterial puncture |
|
Preparation Method |
Male CD-1 mice were anesthetized and subjected to SAH induction via intra-arterial puncture. Dorsomorphin was administered via tail vein injection at 1h after successful SAH modeling. Mice were allocated into 4 groups: sham, SAH+vehicle, SAH+recombinant human GPNMB (rGPNMB, 3.3μg/10μL, intracerebroventricular injection at 1h post-SAH) and SAH+Dorsomorphin. |
|
Dosage form |
10mg/kg; i.v.; single injection at 1h post-SAH |
|
Applications |
Dorsomorphin reduced the rGPNMB-elevated p-AMPK/AMPK ratio in SAH mice, reversed the rGPNMB-mediated downregulation of p-NFκB, IL-1β, IL-6 and TNF-α at both protein and secretion levels, and counteracted the alleviative effects of rGPNMB on brain edema, blood-brain barrier impairment and neurological deficits in SAH mice. |
References: [1] Jia J, Ji W, Saliba AN, et al. AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death. Cell Death Differ. 2024;31(3):405-416. [2] Li T, Zhang Y, Lu Q, et al. GPNMB Ameliorates Neuroinflammation Via the Modulation of AMPK/NFkB Signaling Pathway After SAH in Mice. J Neuroimmune Pharmacol. 2023;18(6):628-639. | |
| Cas No. | 866405-64-3 | SDF | |
| Synonyms | Compound C | ||
| Chemical Name | 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine | ||
| Canonical SMILES | C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC=C5)N=C3 | ||
| Formula | C24H25N5O | M.Wt | 399.49 |
| Solubility | 5mg/ml in DMSO with ultrasonic and warming | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5032 mL | 12.516 mL | 25.0319 mL |
| 5 mM | 500.6 μL | 2.5032 mL | 5.0064 mL |
| 10 mM | 250.3 μL | 1.2516 mL | 2.5032 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data

ATF4 is required for glucose deprivation-induced fructolysis. a, b U87 and LN229 cells treated without or with glucose deprivation for 18 hours in the absence or presence of indicated inhibitors were analyzed by quantitative PCR (a) and immunoblotting with indicated antibodies (b).Data were normalized with β-actin mRNA levels and presented as relative mRNA expression level (a).
GCN2-IN-2 (A-92) (#GC32771-5) and Compound C (#GC17243) were obtained from GLPBIO.
Nature Communications 13.1 (2022): 6108. PMID: 36245009 IF: 16.6009 -
Related Biological Data

MSCs activated autophagy by regulating the AKT/mTOR and AMPK/mTOR signaling pathways to reduce the intracellular mutant protein ataxin-3. D The effect of LY303511 and dorsomorphin on the expression of levels of p-AKT, p-mTOR, ataxin-3, and autophagy-related proteins after MSCs therapy.
Dorsomorphin (10 μM) was purchased from Glpbio (California, USA).
Cell Death & Disease 13.7 (2022): 622. PMID: 35851059 IF: 9.0002 -
Related Biological Data

Role of AMPK in the regulation of CTR1 expression by glucose restriction. (C) The AMPK inhibitor Compound C (40 μM) was used to verify the effect of AMPK on CTR1 expression for 24 h.
Compound C (AMPK inhibitor) was purchased from GlpBio (Shanghai,China).
Cancer Letters (2022): 215793. PMID: 35716782 IF: 8.6796 -
Related Biological Data

tPA regulates glycolysis through AMPK-Glut1 axis. (C) Protein expression of FN, p-AMPK, AMPK, Glut1, PCNA in the MRC-5 cells.
Dorsomorphin (Compound C, GC17243) were purchased from Glpbio Technology (Montclair, CA, USA).
Ecotox Environ Safe 271 (2024): 115994. PMID: 38262094 IF: 6.7996 -
Related Biological Data

Selection and mechanism of the MTND therapy.(a) The cell morphology (bright field image) of tumor cells in its normal state (without any drug treatment); (b) tumor cell morphology (bright field image) under other drug combinations (Retinoic acid, Dorsomorphin, Purmorphamine,P7C3-A20);
The cells were cultured in DMEM/F12 containing MTND (10 μM Forskolin,1 μM Dorsomorphin(Glpbio), 1 μM Purmorphamine, 3 μM CHIR99021 and 3 μM P7C3-A20) or 0.1% DMSO in control groups.
Int J Mol Sci 24.15 (2023): 12329. PMID: 37569705 IF: 5.5999 -
Related Biological Data

p53/AMPK/mTOR pathway was required for S100P-mediated autophagy regulating chemosensitivity. F. HL-60 and Jurkat cells were transfected with S100P shRNA or control shRNA and then pre-treated with Compound C (20 μM) for 6 h.
Compound C and lysosomal protease inhibitors E64d, pepstatin A were purchased from GlpBio (Montclair, CA, USA);
Am J Cancer Res 14.3 (2024): 1121. PMID: 38590396 IF: 5.2999
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)